000169803 001__ 169803
000169803 005__ 20240229133655.0
000169803 0247_ $$2doi$$a10.1016/j.jtho.2021.06.025
000169803 0247_ $$2pmid$$apmid:34245914
000169803 0247_ $$2ISSN$$a1556-0864
000169803 0247_ $$2ISSN$$a1556-1380
000169803 0247_ $$2altmetric$$aaltmetric:109166647
000169803 037__ $$aDKFZ-2021-01557
000169803 041__ $$aEnglish
000169803 082__ $$a610
000169803 1001_ $$aSaalfeld, Felix C$$b0
000169803 245__ $$aBrief Report: Efficacy of immune checkpoint inhibitors alone or in combination with chemotherapy in NSCLC harboring ERBB2 mutations.
000169803 260__ $$aAmsterdam$$bElsevier$$c2021
000169803 3367_ $$2DRIVER$$aarticle
000169803 3367_ $$2DataCite$$aOutput Types/Journal article
000169803 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1642167500_13476
000169803 3367_ $$2BibTeX$$aARTICLE
000169803 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000169803 3367_ $$00$$2EndNote$$aJournal Article
000169803 500__ $$a2021 Nov;16(11):1952-1958
000169803 520__ $$aIn contrast to other driver mutations, no targeted therapies have yet been approved in ERBB2 mutated non-small cell lung cancer (HER2mu NSCLC). However, several compounds have shown promising early efficacy data, which need to be evaluated in the context of current standard approaches. While data on the efficacy of immune checkpoint inhibitors (ICI) in second or later lines of treatment remain limited and conflicting, there are virtually no data on patient outcome under ICI / platinum doublet combinations in the first-line setting.We retrospectively assessed outcomes of HER2mu NSCLC patients treated with ICI alone or in combination with chemotherapy within the German nNGM consortium by means of overall response rate (ORR), progression-free, and overall survival (PFS and OS).ICI either in combination with chemotherapy or as monotherapy were applied as first-line treatment in 27 patients, whereas 34 received single agent ICI in second or later lines. Patient characteristics were in line with previously published data. In treatment-naïve patients receiving ICI in combination with chemotherapy the ORR, median PFS, and OS rate at 1 year were 52%, 6 months, and 88%, respectively. In second or later lines ICI monotherapy was associated with an ORR of 16%, a median PFS of 4 months, and a median OS of 10 months.Immune checkpoint inhibitors are effective as monotherapy and in combination with platinum doublet chemotherapy. Therefore, ICI based treatments may be seen as the current standard of care and benchmark for targeted therapies in HER2mu NSCLC.
000169803 536__ $$0G:(DE-HGF)POF4-311$$a311 - Zellbiologie und Tumorbiologie (POF4-311)$$cPOF4-311$$fPOF IV$$x0
000169803 588__ $$aDataset connected to CrossRef, PubMed, , Journals: inrepo01.inet.dkfz-heidelberg.de
000169803 650_7 $$2Other$$aHER2
000169803 650_7 $$2Other$$aImmunotherapy
000169803 650_7 $$2Other$$aNSCLC
000169803 7001_ $$aWenzel, Carina$$b1
000169803 7001_ $$aChristopoulos, Petros$$b2
000169803 7001_ $$aMerkelbach-Bruse, Sabine$$b3
000169803 7001_ $$aReissig, Timm M$$b4
000169803 7001_ $$aLaßmann, Silke$$b5
000169803 7001_ $$aThiel, Sebastian$$b6
000169803 7001_ $$aStratmann, Jan A$$b7
000169803 7001_ $$aMarienfeld, Ralf$$b8
000169803 7001_ $$aBerger, Johannes$$b9
000169803 7001_ $$aDesuki, Alexander$$b10
000169803 7001_ $$aVelthaus, Janna-Lisa$$b11
000169803 7001_ $$aKauffmann-Guerrero, Diego$$b12
000169803 7001_ $$aStenzinger, Albrecht$$b13
000169803 7001_ $$aMichels, Sebastian$$b14
000169803 7001_ $$aHerold, Thomas$$b15
000169803 7001_ $$aKramer, Michael$$b16
000169803 7001_ $$aHerold, Sylvia$$b17
000169803 7001_ $$aTufman, Amanda$$b18
000169803 7001_ $$0P:(DE-He78)1eee9e84c0f8c90a97fe40b6e8252a23$$aLoges, Sonja$$b19$$udkfz
000169803 7001_ $$aAlt, Jürgen$$b20
000169803 7001_ $$aJoosten, Maria$$b21
000169803 7001_ $$aSchmidtke-Schrezenmeier, Gerlinde$$b22
000169803 7001_ $$aSebastian, Martin$$b23
000169803 7001_ $$aStephan-Falkenau, Susann$$b24
000169803 7001_ $$aWaller, Cornelius F$$b25
000169803 7001_ $$aWiesweg, Marcel$$b26
000169803 7001_ $$aWolf, Jürgen$$b27
000169803 7001_ $$aThomas, Michael$$b28
000169803 7001_ $$aAust, Daniela E$$b29
000169803 7001_ $$aWermke, Martin$$b30
000169803 7001_ $$aCancer, nNGM Lung$$b31$$eCollaboration Author
000169803 773__ $$0PERI:(DE-600)2223437-8$$a10.1016/j.jtho.2021.06.025$$gp. S1556086421022929$$n11$$p1952-1958$$tJournal of thoracic oncology$$v16$$x1556-0864$$y2021
000169803 909CO $$ooai:inrepo02.dkfz.de:169803$$pVDB
000169803 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)1eee9e84c0f8c90a97fe40b6e8252a23$$aDeutsches Krebsforschungszentrum$$b19$$kDKFZ
000169803 9131_ $$0G:(DE-HGF)POF4-311$$1G:(DE-HGF)POF4-310$$2G:(DE-HGF)POF4-300$$3G:(DE-HGF)POF4$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vZellbiologie und Tumorbiologie$$x0
000169803 9130_ $$0G:(DE-HGF)POF3-311$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vSignalling pathways, cell and tumor biology$$x0
000169803 9141_ $$y2021
000169803 915__ $$0StatID:(DE-HGF)0410$$2StatID$$aAllianz-Lizenz$$d2021-01-26$$wger
000169803 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bJ THORAC ONCOL : 2019$$d2021-01-26
000169803 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS$$d2021-01-26
000169803 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline$$d2021-01-26
000169803 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List$$d2021-01-26
000169803 915__ $$0StatID:(DE-HGF)0160$$2StatID$$aDBCoverage$$bEssential Science Indicators$$d2021-01-26
000169803 915__ $$0StatID:(DE-HGF)1110$$2StatID$$aDBCoverage$$bCurrent Contents - Clinical Medicine$$d2021-01-26
000169803 915__ $$0StatID:(DE-HGF)0113$$2StatID$$aWoS$$bScience Citation Index Expanded$$d2021-01-26
000169803 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection$$d2021-01-26
000169803 915__ $$0StatID:(DE-HGF)9910$$2StatID$$aIF >= 10$$bJ THORAC ONCOL : 2019$$d2021-01-26
000169803 9201_ $$0I:(DE-He78)A420-20160331$$kA420$$lPersonalisierte Medizinische Onkologie$$x0
000169803 980__ $$ajournal
000169803 980__ $$aVDB
000169803 980__ $$aI:(DE-He78)A420-20160331
000169803 980__ $$aUNRESTRICTED